Researchers in the U.S. have developed a tool to help predict mortality risk in people with chronic lung disease and pulmonary hypertension (PH). The tool, PVD-B65, accounts for risk factors related to both conditions, including age, lung disease type, PH severity, exercise capacity, and blood levels of a heart…
Read more
We can be tempted to push ourselves when we’re feeling OK and having a not-so-bad day with pulmonary hypertension (PH). Plans with family, weekends packed with activities, or even the excitement of feeling better than usual can make us want to do it all. But those of us with…
Corsair Pharma successfully completed preclinical studies testing its skin patch delivery system for treprostinil as a treatment for pulmonary arterial hypertension (PAH), and is now planning to launch a Phase 1 clinical trial in the next few months. That’s according to new updates from the U.S.-based company, which…
Get regular updates to your inbox.
